# TREML1

## Overview
TREML1 is a gene that encodes the protein known as triggering receptor expressed on myeloid cells-like 1 (TLT-1), which is a member of the TREM family of receptors. TLT-1 is a transmembrane receptor characterized by an extracellular immunoglobulin-like domain, a transmembrane region, and a cytoplasmic tail, which are typical features of the TREM family (Viertlboeck2006The; Qiao2024Tumororiginated). This protein is predominantly expressed in megakaryocytes and platelets, where it plays a crucial role in platelet aggregation and immune response regulation. TLT-1 is stored in α-granules within platelets and translocates to the cell surface upon activation, facilitating interactions with fibrinogen and other molecules to stabilize clot formation (Glembotsky2018Downregulation; Branfield2021The). Beyond its role in hemostasis, TLT-1 is involved in modulating immune responses, particularly in inflammatory conditions such as sepsis, by influencing platelet-neutrophil interactions and leukocyte activation (Glembotsky2018Downregulation). The gene's expression and function have clinical significance, with implications in disorders such as familial platelet disorder and certain cancers, where alterations in TREML1 expression can impact disease progression and patient outcomes (Glembotsky2018Downregulation; Qiao2024Tumororiginated).

## Structure
TREML1 is a member of the TREM family, characterized by an extracellular immunoglobulin-like domain, a transmembrane region, and a cytoplasmic tail. The protein structure of TREML1 includes a V-set Ig domain, which is a common feature in the TREM family, providing a framework for potential interactions with other molecules (Viertlboeck2006The; Qiao2024Tumororiginated). The N290K alteration in the V-set domain of TREML1 has been identified, although it does not accelerate tumor occurrence (Qiao2024Tumororiginated). 

Post-translational modifications of TREML1 may include glycosylation, which is typical for proteins with extracellular domains, potentially affecting its stability and interactions. TREML1 is involved in immune response and platelet function, with its expression regulated by the RUNX1 transcription factor, which influences its role in megakaryocytes and platelets (Glembotsky2018Downregulation). 

The protein may exist in different splice variant isoforms, which can alter its structure and function, although specific details on these variants are not provided in the context. The structural characteristics of TREML1 contribute to its function as an immunoregulatory receptor, impacting processes like platelet aggregation and immune cell interaction (Glembotsky2018Downregulation).

## Function
TREML1 encodes the TREM-like transcript-1 (TLT-1) protein, which plays a significant role in platelet biology. TLT-1 is primarily expressed in megakaryocytes and platelets, where it is stored in α-granules and translocates to the cell surface upon platelet activation (Glembotsky2018Downregulation). This protein is involved in platelet aggregation by interacting with fibrinogen, facilitating the formation of higher-order platelet aggregates, and stabilizing clot formation (Branfield2021The). TLT-1 also interacts with ERM proteins, potentially linking fibrinogen to the platelet cytoskeleton, which is crucial for platelet function (Glembotsky2018Downregulation).

The soluble form of TLT-1 (sTLT-1) is released upon platelet activation and enhances platelet aggregation in a dose-dependent manner (Branfield2021The). TLT-1's role extends to immune functions, as it can dampen inflammation and organ damage during sepsis by counteracting leukocyte activation and platelet-neutrophil crosstalk (Glembotsky2018Downregulation). In Treml1-null mice, the absence of TLT-1 results in mild thrombocytopenia, decreased platelet aggregation, and prolonged bleeding time, underscoring its essential role in maintaining vascular integrity and hemostasis (Washington2009TREMlike).

## Clinical Significance
Mutations and alterations in the expression of the TREML1 gene have been implicated in several diseases and conditions. In familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML), TREML1 is downregulated, leading to decreased levels of TLT-1, a protein encoded by TREML1, in platelets and megakaryocytes. This downregulation is associated with platelet dysfunction, as TLT-1 plays a role in platelet activation and aggregation. The deficiency of TLT-1 in FPD/AML patients contributes to impaired platelet function and aggregation, potentially due to RUNX1 mutations that affect TREML1 expression (Glembotsky2018Downregulation).

In lung cancer, TREML1 is identified as a predictive biomarker for tumorigenesis. Its expression levels are significantly higher in lung cancer tissues compared to normal tissues, and high TREML1 expression is associated with poorer overall survival and disease-free survival in patients. TREML1 mutations, although rare, have been observed in lung adenocarcinoma and lung squamous cell carcinoma. The gene's expression is linked to clinical features such as proliferation, invasion, and metastasis, suggesting its role in cancer progression (Qiao2024Tumororiginated).

Additionally, rare variants in the TREML1 gene cluster have been investigated in the context of Alzheimer's disease, although specific implications for TREML1 itself remain less clear (Ghani2016Mutation).

## Interactions
TREML1, a member of the TREM family, is known to participate in several protein interactions that are crucial for its role in immune response regulation. One of the primary interactions of TREML1 is with DAP12, an adaptor protein that transmits activation signals. This interaction is significant as it facilitates the transmission of activation signals, which are essential for the modulation of immune responses.

In addition to its interaction with DAP12, TREML1 is implicated in platelet function. It may interact with ligands present on other cells, which can influence immune and inflammatory responses. These interactions suggest that TREML1 plays a role in the complex network of immune signaling, potentially affecting both innate and adaptive immune responses.

The interactions of TREML1 with other proteins and ligands highlight its multifaceted role in immune regulation and platelet function. These interactions are crucial for understanding the broader implications of TREML1 in immune system dynamics and its potential impact on inflammatory diseases.


## References


[1. (Viertlboeck2006The) Birgit C. Viertlboeck, Ramona Schmitt, and Thomas W. Göbel. The chicken immunoregulatory receptor families sirp, trem, and cmrf35/cd300l. Immunogenetics, 58(2–3):180–190, February 2006. URL: http://dx.doi.org/10.1007/s00251-006-0091-8, doi:10.1007/s00251-006-0091-8. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00251-006-0091-8)

2. (Qiao2024Tumororiginated) Tumor-originated exosomal TREML1 is a novel predictive biomarker for tumorigenesis in lung cancer. This article has 0 citations.

[3. (Branfield2021The) Siobhan Branfield and A. Valance Washington. The enigmatic nature of the triggering receptor expressed in myeloid cells -1 (tlt- 1). Platelets, 32(6):753–760, February 2021. URL: http://dx.doi.org/10.1080/09537104.2021.1881948, doi:10.1080/09537104.2021.1881948. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/09537104.2021.1881948)

[4. (Glembotsky2018Downregulation) Ana C. Glembotsky, Dominika Sliwa, Dominique Bluteau, Nathalie Balayn, Cecilia P. Marin Oyarzún, Anna Raimbault, Marie Bordas, Nathalie Droin, Iryna Pirozhkova, Valance Washington, Nora P. Goette, Rosana F. Marta, Rémi Favier, Hana Raslova, and Paula G. Heller. Downregulation of trem-like transcript-1 and collagen receptor α2 subunit, two novel runx1-targets, contributes to platelet dysfunction in familial platelet disorder with predisposition to acute myelogenous leukemia. Haematologica, 104(6):1244–1255, December 2018. URL: http://dx.doi.org/10.3324/haematol.2018.188904, doi:10.3324/haematol.2018.188904. This article has 16 citations.](https://doi.org/10.3324/haematol.2018.188904)

[5. (Ghani2016Mutation) Mahdi Ghani, Christine Sato, Erfan Ghani Kakhki, J. Raphael Gibbs, Bryan Traynor, Peter St George-Hyslop, and Ekaterina Rogaeva. Mutation analysis of the ms4a and trem gene clusters in a case-control alzheimer’s disease data set. Neurobiology of Aging, 42:217.e7-217.e13, June 2016. URL: http://dx.doi.org/10.1016/j.neurobiolaging.2016.03.009, doi:10.1016/j.neurobiolaging.2016.03.009. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.neurobiolaging.2016.03.009)

[6. (Washington2009TREMlike) A. Valance Washington, Sébastien Gibot, Ismael Acevedo, James Gattis, Laura Quigley, Robert Feltz, Alina De La Mota, Rebecca L. Schubert, Julio Gomez-Rodriguez, Jun Cheng, Amalia Dutra, Evgenia Pak, Oleg Chertov, Linette Rivera, Jessica Morales, Jacek Lubkowski, Robert Hunter, Pamela L. Schwartzberg, and Daniel W. McVicar. Trem-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. Journal of Clinical Investigation, 119(6):1489–1501, June 2009. URL: http://dx.doi.org/10.1172/jci36175, doi:10.1172/jci36175. This article has 100 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci36175)